13 doernberg emerginginfx - ucsf cme doernberg emerginginf… · • if(doxyisnotan opon ... •...
TRANSCRIPT
4/25/13
1
Emerging Infec,ons
Sarah Doernberg, MD Assistant Professor
University of California, San Francisco April 25, 2013
Disclosures
• Nothing to disclose
Outline
• What is an emerging infec,on? • West Nile virus
• Hantavirus • Lyme and other Jck-‐borne illnesses
• Novel coronavirus • H7N9
What is an emerging infec,on?
• Infec,on that has newly appeared in the popula,on, or have existed but are rapidly increasing in incidence or geographic range
• Many historical examples: – Plague – Smallpox – Influenza
Morse SS. Emerg Infect Dis. 1995 Jan-‐Mar;1(1):7-‐15; Spellberg B. Clin Infect Dis 2008;47:294.
4/25/13
2
Morens DM, et al. Nature 430, 242-‐249(8 July 2004)
Worldwide emerging infec,ons Outline
• What is an emerging infecJon? • West Nile virus
• Hantavirus • Tick-‐borne illnesses • Novel coronavirus • H7N9
WNV Outbreak
• CDC declared an outbreak in August, 2012 • Focused in Dallas, TX, but ac,vity in all 48 con,nental states
• Most cases in history of disease in USA
• 2734 neuroinvasive cases, 243 deaths
West Nile virus neuroinvasive disease, 2011
h[p://www.cdc.gov/ncidod/dvbid/westnile/Mapsincidence/surv&control11IncidbyState.htm
4/25/13
3
West Nile virus neuroinvasive disease, 2012
h[p://www.cdc.gov/ncidod/dvbid/westnile/Mapsincidence/surv&control12IncidbyState.htm
WNV background
• First isolated in 1937 from the West Nile district of Uganda
• Part of the Japanese encephali,s virus family: Includes JE, St Louis encephali,s, others
• Widely distributed throughout the world • First reported in USA in 1999 – Cluster of neuroinvasive disease recognized in Queens
• Limited ac,vity un,l 2002 when there was an epidemic with ↑severity
h[p://www.cdc.gov/ncidod/dvbid/westnile/cycle.htm
Rare Spread of WNV
• Mosquito bite • Breastmilk
• Blood • Transplacental • Organ transplantaJon • OccupaJonal exposure (lab work)
4/25/13
4
Clinical presenta,on
• Incuba,on 2-‐14 days • Vast majority of infec,ons are asymptoma,c • 20% WNV fever: Fever, myalgias, malaise, HA – +/-‐rash (25-‐50%), +/-‐ LAD (rare)
• <1% Neuroinvasive disease – Encephali,s – Meningi,s – Flaccid paralysis (polio-‐like syndrome)
• Immunity is thought to be lifelong
Risk factors for severe WNV Factor Odds ra,o 95% CI
Age
18-‐59 y Ref Ref
60-‐69 y 2.0 1.4-‐3.0
≥ 70 y 6.5 3.9-‐10.7
Male 1.4 1.0-‐1.8
Race other than white, non-‐Hispanic
2.9 2.0-‐4.2
Hypertension 1.5 1.1-‐2.1
Diabetes 2.2 1.4-‐3.4
Any history of cancer (non-‐BCC) 3.7 1.8-‐7.5
Chronic renal disease 4.1 1.4-‐12.1
EtOH abuse 3.0 1.3-‐6.7 Lindsey NP, et al. Am J Trop Med Hyg. 2012 Jul;87(1):179-‐84.
WNV sequelae
• RNA detected even years aker infec,on • Fa,gue levels normalize in ~4 months • > 50% with soma,c complaints at 1 year • Abnormal neurocogni,ve tes,ng in some – Motor speed, manual dexterity, execu,ve func,oning,
memory
• New tremor in up to 20% Murray K, et al. J Infect Dis 2010;201(1):2. Loeb M, et al. Ann Intern Med 2008;149(4):232. Carson PJ, et al. Clin Infect Dis. 2006;43(6):723.
Diagnosis of WNV
Busch MP, et al. J Infect Dis. 2008 Oct 1;198(7):984-‐93
Viral RNA
IgM
IgG
Mosquito bite
~2 days
~13 days
~4 days ~3 days
4/25/13
5
WNV diagnosis
• Serum or CSF IgM – Can persist up to 6 months
– May need convalescent ,ters if ini,ally nega,ve – False posi,ves: Yellow fever/JE vaccines, dengue or other flavivirus infec,on
• Serum or CSF nucleic acid tes,ng (PCR) – Lower sensi,vity – Can be helpful in immunocompromised pts
Preven,on
• Avoid mosquito bites! • Use EPA-‐approved insect repellants:
– hpp://cfpub.epa.gov/oppref/insect/ for list – DEET (okay to use with sunscreen) – Picaridin – Oil of Lemon Eucalyptus or PMD, the synthesized version – IR3535
• Screens on windows/doors • No standing water • Aerial spraying • Screen blood donors • Vaccine (phase I/II promising), equine licensed
h[p://www.cdc.gov/ncidod/dvbid/westnile/wnv_factsheet.htm Peterson LR and Fischer M. N Engl J Med. 2012 Oct 4;367(14):1281-‐4.
Management
• Suppor,ve care • RCTs for novel therapies have failed due to low enrollment – Intravenous immunoglobulin – Interferon alpha – Ribavirin
Peterson LR, Fischer M.. N Engl J Med. 2012 Oct 4;367(14):1281-‐4; Agrawal AG, Petersen LR. J Infect Dis. 2003 Jul 1;188(1):1-‐4. Kalil AC, et al. Clin Infect Dis. 2005 Mar 1;40(5):764-‐6; Hrnicek MJ, Mailliard ME. Am J Gastroenterol. 2004;99(5):957. Chowers MY, et al. Emerg Infect Dis. 2001 Jul-‐Aug;7(4):675-‐8.
WNV take-‐home points
• Generally transmiped by mosquitos • Most infec,ons are asymptoma,c
• Can cause severe CNS disease • Diagnose with serum IgM
• Prevent mosquito bites!
• Suppor,ve care
4/25/13
6
Outline
• What is an emerging infecJon? • West Nile virus
• Hantavirus • Lyme and other Jck-‐borne illnesses
• Novel coronavirus • H7N9
Hantavirus outbreak • 8/16/12: CADPH reports hantavirus in 2 visitors to Curry Village, Yosemite NP – Closure of Curry Village
• 8/31: CDC issues a na,onal health advisory • 9/6: An individual staying at other Yosemite camps also becomes ill
• 9/12: All overnight visitors to Yosemite warned of risk
• 11/1: 10 confirmed cases, 3 deaths total
Hantavirus background
• Many viral species exist: – Old World: Hemorrhagic fever w/ renal syndrome (HFRS)
– New World: Hantavirus cardiopulmonary sx (HCPS)
• Outbreaks throughout history • First described by Western Medicine in 1950s aker HFRS outbreak among UN troops
• 1993: HCPS recognized in USA at New Mexico-‐Arizona border (sin Nombre virus)
4/25/13
7
Hantavirus transmission in the USA
Deer mouse Co[on rat
Rice rat
White-‐footed rat
h[p://www.cdc.gov/hantavirus/rodents/index.html
• Inhala,on of urine or droppings
• Direct contact with urine or droppings
• Rodent bite • Person-‐to-‐person?
h[p://www.cdc.gov/hantavirus/surveillance/state-‐of-‐exposure.html
HCPS clinical presenta,on
• Incuba,on: ~2-‐3 weeks • Prodrome (2-‐8 days): Fevers/myalgias progressing to nausea, vomi,ng, weakness, headaches
– Absent URI symptoms • Cardiopulmonary phase (2-‐7 days): Dry coughabrupt onset of shock, noncardiogenic pulmonary edema, coagulopathy
• Oliguric/diure,c: Less prominent than HFRS
• Convalescent (48 hours-‐much longer)
HCPS diagnosis • Radiographic findings: B inters,,al infiltrates • Laboratory findings:
– Thrombocytopenia occurs early – Lek shik with immunoblasts (>10% of lymphoid series)
– Less specific: ↑LDH, ↑lactate, hepa,,s, anemia, coagulopathy
• Serology: IgM + by symptom onset in acute infec,on, fourfold rise in IgG (not FDA approved)
• RT-‐PCR less useful
4/25/13
8
HCPS preven,on
• Avoid rodent contact
• Air out buildings • Clean with dilute bleach • Wear gloves
Seal up Trap up Clean up
h[p://www.cdc.gov/hantavirus/hps/prevenJon.html
HCPS treatment
• Suppor,ve care – Early vasopressor use and cau,ous volume resuscita,on
– Considera,on of ECMO
• Ribavirin – In vitro ac,vity – Mortality in HFRS 2/2 Hantaan virus: 8.5% placebo vs. 2.4% IV ribavirin (p = 0.04)
– Anemia is major SE – 2 studies with HCPS did not show clear benefit but small
Huggins JW, et al. J Infect Dis 1991 Dec;164(6):1119-‐27. Chapman LE, et al. AnJvir Ther. 1999;4(4):211 Mertz GJ, et al. Clin Infect Dis. 2004;39(9):1307.
HCPS take-‐home points
• Transmiped by rodents • Nonspecific prodrome evolving into severe respiratory illness
• Laboratory abnormali,es can help to make diagnosis
• Avoid rodents and clean up responsibly • Suppor,ve care +/-‐ ribavirin
Outline
• What is an emerging infecJon? • West Nile virus
• Hantavirus • Lyme and other ,ck-‐borne illnesses
• Novel coronavirus • H7N9
4/25/13
9
Tick background
h[p://www.cdc.gov/Jcks/life_cycle_and_hosts.html
Diseases transmiped by ,cks
• Anaplasmosis (Ixodes sp.) • Babesiosis (Ixodes scapularis) • Erlichiosis (Ambylomma americanum) • Lyme disease (Ixodes sp.) • Borrelia miyamotoi (Ixodes scapularis) • R. parkeri (Ambylomma maculatum) • RMSF (Dermacentor sp., brown dog ,ck) • Tickborne relapsing fever (sok ,cks) • Tularemia (Dermacentor sp., Ambylomma sp.) • 364D Rickepsiosis (Dermacentor occidentalis) • Abroad: Crimean-‐Congo hemorrhagic fever, rickepsial spoped
fevers (esp. R. africae), ,ckborne encephali,s
h[p://www.cdc.gov/lyme/stats/maps/map2011.html
Lyme background
• Caused by a spirochete – In USA, Borrelia burgdorferi – In Europe, B. afzelii, B. garinii > B. burgdorferi
• Transmiped by Ixodes ,cks, which can spread other diseases: – USA: Human granulocy,c anaplasmosis, babesiosis
– Europe: Tick-‐borne encephali,s • Require > 48 hrs of apachment but less important for other ,ckborne illnesses
4/25/13
10
h[ps://vpn.ucsf.edu/lyme/transmission/,DanaInfo=www.cdc.gov+blacklegged.html
How to remove a ,ck
h[p://www.cdc.gov/Jcks/removing_a_Jck.html
Early localized Lyme
• 3-‐30 days aker ,ck bite • 80% of pa,ents • 25% recall ,ck bite • Erythema migrans
– May start solid, then develop central clearing – Mul,ple EM lesions in up to 20% – Similar lesion in STARI
• Nonspecific flu-‐like symptoms
Early disseminated Lyme
• Weeks to months aker bite • Neurologic:
– Meningi,s (lymphocy,c)
– Cranial nerve palsies (esp facial) – Other neuropathies
• Cardi,s: AV block, myopericardi,s
• Ocular: Conjunc,vi,s > others • +/-‐ arthralgias, systemic symptoms
4/25/13
11
Late disseminated Lyme
• Months to years aker ,ck bite • Arthri,s:
– Intermipent or persistent
– Large joints (knee)
• Neurologic: – Lyme encephalopathy – Chronic axonal neuropathyspinal radicular pain, distal paresthesias
• Skin: Acroderma,,s chronica atrophicans (Europe)
Post Lyme syndrome
• Most people respond well to an,bio,cs • Minority have ongoing subjec,ve symptoms
– Fa,gue, MSK pain, cogni,ve complaints
• “Lyme-‐literate” physicians believe that B. burgdorferi infec,on is the culprit – Diagnosis on clinical grounds – Use of unvalidated tes,ng or different cut-‐offs – Long courses of an,bio,cs rx’d
Feder HM Jr., et al. N Engl J Med 2007 Oct 4;357(14):1422-‐30
Four categories of “chronic” Lyme
1. Symptoms of unknown cause with no evidence of B. burgdorferi infec,on
2. A well-‐defined illness unrelated to Lyme (e.g. MS)
3. Symptoms of unknown cause with serologic evidence of B. burgdorferi but no objec,ve findings
4. Post-‐lyme disease syndrome, previous treatment with ongoing symptoms
• For further advice about managing these pa,ents: – Supplement to: Feder HM Jr, Johnson BJB, O’Connell S, et al. N Engl J
Med 2007;357:1422-‐30. Feder HM Jr., et al. N Engl J Med 2007 Oct 4;357(14):1422-‐30
Coinfec,on
Region Lyme Anaplasma Babesia Coinfec,on 2 pathogens
Coinfec,on 3 pathogens
CA 4-‐7% 3-‐7% -‐-‐ 1-‐1.3% -‐-‐
NE 22-‐52% 2-‐53% 1-‐23% 1-‐28% 0
WI 11% 8% -‐-‐ 2% -‐-‐
Swanson SJ, et al. Clin Microbiol Rev 2006 Oct;19(4):708-‐27
• Coinfec,on reported in 2-‐40% of pa,ents diagnosed with Lyme disease (most studies in NE) • Most frequently babesia + lyme • Consider if failure to respond to an,bio,cs or CBC abnormali,es
4/25/13
12
h[p://www.cdc.gov/lyme/healthcare/clinician_twoJer.html
What not to send
• Capture assays for an,gens in urine • Culture, immunofluorescence staining, or cell sor,ng of cell
wall-‐deficient or cys,c forms of B. burgdorferi • Lymphocyte transforma,on tests • Quan,ta,ve CD57 lymphocyte assays • “Reverse Western blots” • In-‐house criteria for interpreta,on of immunoblots • Measurements of an,bodies in joint fluid (synovial fluid) • IgM or IgG tests without a previous ELISA/EIA/IFA
h[p://www.cdc.gov/lyme/diagnosistesJng/LabTest/OtherLab/index.html
MMWR, CDC Surveillance Summary, 2005, 54:125.
Lyme disease prophylaxis
• If all criteria met: – Tick is adult or nymphal Ixodes scapularis
– Tick apached at least 36 hours – Prophylaxis is begun w/i 72 hours of ,ck removal – Local rate of ,ck infec,on at least 20% – Doxycycline is not contraindicated
• Doxycycline 200 mg PO x 1 dose
• If doxy is not an op,onwatchful wai,ng
Wormser GP, et al. Clin Infect Dis 2006; 43:1089
Treatment Syndrome Doxycycline
100 mg q12h Amoxicillin 500 mg TID
Cefuroxime 500 mg Q12h
Cekriaxone 2 g IV qday
EM 10-‐21 d 14-‐21 d 14-‐21 d
CN VII palsy 14-‐28 d
Other neurologic 10-‐28 d
1st degree AV block 14-‐21 d 14-‐21 d 14-‐21 d
Other cardi,s 21-‐28 d
Arthri,s alone 28 d 28 d 28 d
Recurrent arthri,s 28 d 28 d 14-‐28 d
Treats HGA Yes No No No
Treats Babesia No No No No
Wormser GP, et al. Clin Infect Dis 2006; 43:1089
4/25/13
13
Lyme take-‐home points
• Requires prolonged exposure to ,ck • Most people have EM rash alone
• Responds well to an,bio,cs • Ongoing symptoms can occur, not treated with further an,bio,cs unless arthri,s
• Diagnose with IFA/ELISA + WB confirma,on
• Consider coinfec,on if ongoing sxs or CBC abnormali,es
Outline
• What is an emerging infecJon? • West Nile virus
• Hantavirus • Lyme and other Jck-‐borne illnesses
• Novel coronavirus • H7N9
Novel coronavirus HCoV-‐EMC • 17 cases reported in 2012-‐13, 11 deaths • Jordan, Saudia Arabia, Qatar, UK, UAE • Possible person-‐to-‐person spread • Pa,ent under inves,ga,on:
– Acute respiratory infec,on w/ PNA or ARDS – Travel to Arabian Peninsula or neighbors w/i 10 days – Contact to someone who has recent travel – Nega,ve tes,ng for other e,ologies – Report if cluster of severe respiratory illness in HCW
Zaki AM, et al. N Engl J Med. 2012 Nov 8;367(19):1814-‐20 h[p://www.cdc.gov/coronavirus/ncv/
H7N9 Virus • Influenza A H7 normally circulate among birds – Prior sporadic human infec,ons but not w/ H7N9
• First reported in humans 3/31/13 in China
• Severe pneumonia
• > 100 cases, 21 deaths • Transmission route not known
• Sensi,ve to neuroaminidase inhibitors
4/25/13
14
Respiratory virus take-‐homes
• High index of suspicion needed • When in doubt, report to your local DPH
• Take a travel history! • Infec,on control • Suppor,ve care +/-‐ an,virals
Thank you!
Ques,ons?
Risk factors for neuroinvasive disease
Factor Odds ra,o 95% CI
Diabetes 4.2 2.6–6.6
Age > 64 y 2.2 1.6–3.1
Hypertension 2.1 1.4-‐3.0
Male 1.6 1.2–2.1
Jean CM, et al. Emerg Infect Dis. 2007 Dec;13(12):1918-‐20
WNV and pregnancy
• Mother-‐to-‐child transmission has been reported – CDC registry: report to department of public health
• PrevenJon is key • AsymptomaJc women should not be screened • Okay to conJnue breaspeeding during illness • Clinical evaluaJon of infants
h[p://www.cdc.gov/ncidod/dvbid/westnile/qa/breaspeeding.htm
4/25/13
15
Bacon RM, et al. MMWR Surveill Summ 2008 Oct 3;57(10):1-‐9.
ReinfecJon vs. relapse
• 17 paJents with paired episodes of erythema migrans
• B. burgdorferi isolated from skin or blood culture in research seqng
• All with different genotypes at iniJal and second episode
• Confirms reinfecJon rather than relapse
• Only in early disease because immune response thought not protecJve
Nadelman RB, et al. N Engl J Med. 2012 Nov 15;367(20):1883-‐90.
MeeJng the challenge of emerging infecJons
• Rapid clinical diagnosis • Response and containment
David M. Morens, Gregory K. Folkers & Anthony S. Fauci. Nature 430, 242-‐249(8 July 2004)